GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Easton Pharmaceuticals Inc (OTCPK:EAPH) » Definitions » Return-on-Tangible-Asset

Easton Pharmaceuticals (Easton Pharmaceuticals) Return-on-Tangible-Asset : -16.88% (As of Sep. 2021)


View and export this data going back to . Start your Free Trial

What is Easton Pharmaceuticals Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Easton Pharmaceuticals's annualized Net Income for the quarter that ended in Sep. 2021 was $-0.34 Mil. Easton Pharmaceuticals's average total tangible assets for the quarter that ended in Sep. 2021 was $1.99 Mil. Therefore, Easton Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2021 was -16.88%.

The historical rank and industry rank for Easton Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:

EAPH's Return-on-Tangible-Asset is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.6
* Ranked among companies with meaningful Return-on-Tangible-Asset only.

Easton Pharmaceuticals Return-on-Tangible-Asset Historical Data

The historical data trend for Easton Pharmaceuticals's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Easton Pharmaceuticals Return-on-Tangible-Asset Chart

Easton Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec18 Dec19 Dec20
Return-on-Tangible-Asset
Get a 7-Day Free Trial -340.82 -589.19 -12.91 -5.91 -3.37

Easton Pharmaceuticals Quarterly Data
Jun02 Sep02 Dec02 Mar03 Jun03 Sep03 Dec03 Mar04 Jun04 Sep04 Dec04 Mar05 Jun05 Sep05 Dec18 Dec19 Dec20 Mar21 Jun21 Sep21
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -18.76 -16.65 -16.88

Competitive Comparison of Easton Pharmaceuticals's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Easton Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Easton Pharmaceuticals's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Easton Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Easton Pharmaceuticals's Return-on-Tangible-Asset falls into.



Easton Pharmaceuticals Return-on-Tangible-Asset Calculation

Easton Pharmaceuticals's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2020 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2020 )  (A: Dec. 2019 )(A: Dec. 2020 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2020 )  (A: Dec. 2019 )(A: Dec. 2020 )
=-0.189/( (8.979+2.249)/ 2 )
=-0.189/5.614
=-3.37 %

Easton Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2021 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Sep. 2021 )  (Q: Jun. 2021 )(Q: Sep. 2021 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Sep. 2021 )  (Q: Jun. 2021 )(Q: Sep. 2021 )
=-0.336/( (1.955+2.025)/ 2 )
=-0.336/1.99
=-16.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2021) net income data.


Easton Pharmaceuticals  (OTCPK:EAPH) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Easton Pharmaceuticals Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Easton Pharmaceuticals's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Easton Pharmaceuticals (Easton Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
2 Bloor Street East, Suite 3500, Toronto, ON, CAN, M4W 1A8
Easton Pharmaceuticals Inc is a diversified specialty pharmaceutical company. It owns and develops proprietary transdermal delivery technology and therapeutic over the counter products and drugs to treat cancer and other diseases. The company also owns exclusive distribution rights in Mexico and Latin America for patented women's diagnostic and preventative care products. It is focused on the development of product Viorra. The firm's products include Nauseasol, Skin Renou HA, Kenestrin gel, and XILIVE, among others.

Easton Pharmaceuticals (Easton Pharmaceuticals) Headlines

From GuruFocus

Easton Pharmaceuticals Announces BAYER Agreement Update

By Marketwired Marketwired 04-16-2018